Academic literature on the topic 'Klomifen'

Background: Infertile couple with the cause of unexplained infertility and male factor can follow intrauterine insemination (IUI) program as a cheap and easy method for infertility therapy. Ovarian stimulation by combination of clomiphene citrate and gonadotropin and also clomiphene citrate alone was done as a superovulation mode to get higher number of mature follicle to gain higher pregnancy rate. Objective : To compare the amount of mature follicles and endometrial thickness as an outcome of ovarian stimulation between combination drug of clomiphene citrate and gonadotrophin with clomiphene citrate alone.Methods: Observational retrospective cohort. Subject is one cycle intrauterine insemination stimulated either by combination CC gonadotrophin or CC alone, eligible in inclusion criteria and exclusion criteria. Statistic test used was independent t-test, chi-square and logistic regression.Location of study: Infertility Clinic of Permata Hati, dr. Sardjito Hospital, Yogyakarta.Result: A total of 142 cycle from 98 couples followed IUI and stimulated by combination CC gonadotrophin (n=72) or CC alone (n=70). Multiple mature follicle number was different and statistically significant 77% vs 54%, RR 1,433 (IK95% 1,118-1,836), p=0,005, while endometrial thickness > 7mm was more frequent in combination group but not statistically different with percentage 81,9% vs 74,3%, RR 1,103 (CI95% 0,926-1,315), p=0,367.Conclusion: Ovarian stimulation by combination CC gonadotropin resulting of more multiple mature follicle number while good endometrial thickness was more in combination group but not statistically significant.Keywords: ovarian stimulation, clomiphene citrate, gonadotrophin, multifollicular, endometrial thickness

Abstract: Polycystic ovary syndrome is the most common endocrinopathy in woman of reproductive age with an incidence that causes infertility. Woman who want to have children recomended to use ovulation induction is clomiphene citrate. Expected with the use of clomiphene citrate as first choice therapy has significcant numbers so that the use of drugs is always preffered. Purpose of this research to determine the number of pregnancies in patient with polycystic ovary syndrome with clomiphene citrate. Method used a retrospective descriptive, data of patient who treatment polycystic ovary syndrome in Prof. Dr. R. D. Kandou General Hospital Manado and practice clinical doctor conducted in the form medical therapy with clomiphene citrate. Polycystic ovary syndorme found 35 cases in the year 2012-2014 with 2 cases in Prof. Dr. R. D. Kandou General Hospital Manado and 33 cases in practice clinical doctor. Conceive with clomiphene citrate therapy were 9 people. Available data show clomiphene citrate still as the first choice drug for ovulation induction of polycystic ovary syndrome.Keywords: polycystic ovary syndrome, clomiphene citrate, succsesful, pregnancyAbstrak: Sindrom ovarium polikistik merupakan salah satu endokrinopati paling umum pada wanita usia reproduksi dengan angka kejadian yang menyebabkan infertilitas. Wanita yang ingin mempunyai anak direkomendasikan untuk induksi ovulasi adalah klomifen sitrat. Diharapkan dengan pemberian klomifen sitrat sebagai terapi pilihan pertama mempunyai angka bermakna sehingga penggunaan obat selalu diutamakan. Tujuan Penilitian ini untuk mengetahui jumlah kehamilan pada penderita sindrom ovarium polikistik dengan terapi klomifen sitrat. Metode yang digunakan bersifat retrosepktif deskriptif, data penderita sindrom ovarium polikistik yang berobat di RSUP Prof. Dr. R. D. Kandou Manado dan dokter praktek klinik yang dilakukan terapi berupa klomifen sitrat. Ditemukan 35 kasus sindrom ovarium polikistik dari tahun 2012-2014 dengan 2 kasus terdapat di RSUP Prof Dr. R. D. Kandou dan 33 kasus di dokter praktek klinik. Berhasil hamil dengan terapi klomifen sitrat sebanyak 9 orang. Data yang ada menunjukan klomifen sitrat masih sebagai pilihan pertama obat induksi ovulasi bagi penderita sindrom ovarium polikistik.Kata kunci: sindrom ovarium polikistik, klomifen sitrat, keberhasilan, kehamilan

INTRODUCTION: Most of the obese PCOS patients are resistant to clomiphene citrate standard doses. In these cases metabolic syndromes are treated by using insulin sensitizing drugs so that ovulation can be achieved.In this study rosiglitazine maleat was used in order to induce ovulation in obese clomiphene resistant PCOS patients. METHODS: 30 women(18-40 year old) with clomiphene resistant polycystic ovary syndrome that were obese (BMI>25 kg/m2) and hyperinsulinemic were seperated in two groups. In the first group (n=15) oral antidiabetic Rosiglitazone maleate( 4mg bid) which belongs to thiazolidinediones were used.In the second group(n=15) in addition to clomiphen citrate(50 bid)and Rosiglitazone maleate(4 mg bid) were used, ovulation and pregnancy rates were compared. In both groups ovulation and pregnancy were recorded, in the second group ovulation and pregnancy rates were higher than the first group but these rates were not significant. RESULTS: In group 1, ovulation was achieved in 5 patients (%33) and pregnancy was achieved in 1 patient (%7). In group 2, ovulation was achieved in 9 patients (%60) and pregnancy was achieved in 3 patients (%20).There was no statistical significance between two groups. DISCUSSION AND CONCLUSION: In our study in obese and hyperinsulinemic patients rosiglitazone maleat can induce ovulation and in addition to clomiphene citrate also ovulation can be achieved although it is statistical insignificant. As a result Rosiglitazone maleate can be used alternatively as an insulin sensitizer and ovulation induction agent.

Bakgrund: Infertilitet är ett sjukdomstillstånd som innebär att ett par inte kan uppnå en klinisk graviditet under mer än ett år av försök. Det är mellan 10-15 % av alla par i fertil ålder som drabbas av tillståndet i varje land. Orsaken som hittas i 90 procent av fallen är antingen manliga, kvinnliga eller gemensamma faktorer. När ingen orsak hittas kallas det för oförklarlig-, eller idiopatisk infertilitet. Innan diagnostisering och eventuell behandling utförs därför noga utredningar med analyser på både kvinnan och mannen. Behandlingen bestäms därefter utifrån orsak. Vid kvinnlig infertilitet är in vitro-fertilisering (IVF) den mest vanliga icke-farmakologiska proceduren som används framför allt vid oförklarlig infertilitet och åldersfaktorer. Antiöstrogenet klomifencitrat har i många decennier varit farmakologiska förstahandsbehandlingen vid anovulatorisk infertilitet men vid de senaste 10 åren har den ersätts med aromatashämmaren letrozol som med en liknande mekanism kunnat ge upphov till ovulationsstimulering. Syfte: Syftet med examensarbetet var att utvärdera och jämföra effekterna av antiöstrogenet klomifencitrat med aromatashämmaren letrozol vid infertilitetsbehandling hos kvinnor. Metod: För att uppnå syftet utfördes litteratursökningar av relaterade vetenskapliga studier i den medicinska databasen PubMed. Nyckelorden som användes vid sökning var “female infertility”, “clomiphene” och “letrozole” och därefter hämtades fem randomiserade kontrollerade vetenskapliga artiklar (RCT) som granskades i resultatdelen av arbetet. Resultat: Samtliga studier, utom studie 5, visade att aromatashämmaren letrozol hade bättre effekt på ovulationstimuleringen och därmed också att uppnå klinisk graviditet än vad klomifencitrat hade. Administrering av letrozol ledde också till större tjocklek av endometrium och fler antalet mogna folliklar. Å andra sidan visade sig letrozol ge högre sannolikhet till multipla graviditet i studie 5. Det förekom ett par fall av allvarliga biverkningar under administrering av samtliga läkemedel, dock var majoriteten av biverkningarna milda och förekom i form utav huvudvärk, illamående, gastrointestinala besvär, trötthet och värmevallningar. Slutsats: Resultaten tyder på att letrozol är ett mer effektivt alternativ till infertilitetsbehandling av kvinnor. Eftersom den dessutom har mycket lägre halveringstid än klomifencitrat gör den mer säker att använda då det låg östrogennivå är ej optimal hos kvinnor i fertil ålder.
Background: Infertility is a condition that is based on a couple not being able to achieve a clinical pregnancy for more than a year of trying. Between 10-15 % of all heterosexual couples of childbearing age are affected by the condition in each country. The cause that is found in 90 percent of cases is either male-, female- or common factors. When no cause is found, it is called unexplained or idiopathic infertility. Before diagnosis and possible treatment, careful investigations are therefore performed with analysis on both the woman and the man. The treatment is then determined based on the cause. In female infertility, in vitro fertilization (IVF) is the most common non-pharmacological procedure used primarily for unexplained infertility and age factors. The antiestrogen clomiphene citrate has for many decades been the first-line parmacological treatment for anovulatory infertility, but in the last 10 years it has been replaced by the aromatase inhibitor letrozole, which with a similar mechanism have effect on ovulation stimulation. Aim: The aim of this thesis was to evaluate and compare the treatment effects of the antiestrogen clomiphene citrate with the aromatase inhibitor letrozole in female infertility. Method: A literature search of related scientific studies was implemented in the medical database PubMed. The keywords used in the searchfield were ”female infertility”, ”clomiphene” and ”letrozole” and then five randomized controlled trial articles (RCT) were selected to be reviewed in the results part of the thesis. Results: All studies, except for study 5, showed that the aromatase inhibitor letrozole had a better effect than clomiphene citrate on ovulation stimulation and thus also to achieve a clinical pregnancy. Administration of letrozole also led to greater endometrial thickness and increased numer of mature follicles. In study 5 on the other hand, letrozole was shown to increase the likelihood of multiple pregnancies. There were a couple of cases of serious side effects during the administration of these drugs, however, the majority of the side effects were mild and occured in the form of headaches, nausea, gastrointestinal disorders, fattigue, and hot flashes. Conclusion: In conclusion, the results suggest that letrozole is a more effective alternative to infertility treatment for women. In addition, since it has a much lower half-life than clomiphene citrate, it is safer to use as low estrogen levels are not optimal in women of childbearing potential.